Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

NASDAQ:EOLS - Nasdaq - US30052C1071 - Common Stock - Currency: USD

13.99  -0.63 (-4.31%)

After market: 13.89 -0.1 (-0.71%)

Fundamental Rating

3

Taking everything into account, EOLS scores 3 out of 10 in our fundamental rating. EOLS was compared to 194 industry peers in the Pharmaceuticals industry. EOLS has a bad profitability rating. Also its financial health evaluation is rather negative. EOLS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EOLS has reported negative net income.
EOLS had a negative operating cash flow in the past year.
EOLS had negative earnings in each of the past 5 years.
In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

EOLS's Return On Assets of -24.15% is in line compared to the rest of the industry. EOLS outperforms 60.00% of its industry peers.
With a Return On Equity value of -941.60%, EOLS is not doing good in the industry: 83.78% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -24.15%
ROE -941.6%
ROIC N/A
ROA(3y)-30.87%
ROA(5y)-41.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

The Gross Margin of EOLS (69.94%) is better than 73.51% of its industry peers.
EOLS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for EOLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5YN/A
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EOLS has been increased compared to 1 year ago.
EOLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EOLS is higher compared to a year ago.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

EOLS has an Altman-Z score of -0.10. This is a bad value and indicates that EOLS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EOLS (-0.10) is comparable to the rest of the industry.
A Debt/Equity ratio of 20.58 is on the high side and indicates that EOLS has dependencies on debt financing.
EOLS's Debt to Equity ratio of 20.58 is on the low side compared to the rest of the industry. EOLS is outperformed by 87.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 20.58
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACCN/A
WACC10.25%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.47 indicates that EOLS has no problem at all paying its short term obligations.
EOLS has a Current ratio (2.47) which is comparable to the rest of the industry.
A Quick Ratio of 2.23 indicates that EOLS has no problem at all paying its short term obligations.
EOLS has a Quick ratio (2.23) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 2.23
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.94% over the past year.
Looking at the last year, EOLS shows a very strong growth in Revenue. The Revenue has grown by 34.42%.
The Revenue has been growing by 52.93% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)35.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)34.42%
Revenue growth 3Y52.93%
Revenue growth 5YN/A
Sales Q2Q%22.12%

3.2 Future

Based on estimates for the next years, EOLS will show a very strong growth in Earnings Per Share. The EPS will grow by 45.98% on average per year.
EOLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.76% yearly.
EPS Next Y55.54%
EPS Next 2Y46.12%
EPS Next 3Y49.27%
EPS Next 5Y45.98%
Revenue Next Year32.14%
Revenue Next 2Y32.03%
Revenue Next 3Y32.11%
Revenue Next 5Y28.76%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EOLS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 166.86, the valuation of EOLS can be described as expensive.
73.51% of the companies in the same industry are more expensive than EOLS, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of EOLS to the average of the S&P500 Index (22.68), we can say EOLS is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 166.86
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
EOLS's earnings are expected to grow with 49.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.12%
EPS Next 3Y49.27%

More info and screens

0

5. Dividend

5.1 Amount

EOLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOLUS INC

NASDAQ:EOLS (2/21/2025, 8:15:52 PM)

After market: 13.89 -0.1 (-0.71%)

13.99

-0.63 (-4.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners73.08%
Inst Owner Change2.95%
Ins Owners1.97%
Ins Owner Change-0.23%
Market Cap885.85M
Analysts84.62
Price Target24.19 (72.91%)
Short Float %11.65%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.15%
Min EPS beat(2)-60.88%
Max EPS beat(2)24.59%
EPS beat(4)2
Avg EPS beat(4)-23.98%
Min EPS beat(4)-75.59%
Max EPS beat(4)24.59%
EPS beat(8)6
Avg EPS beat(8)-9.24%
EPS beat(12)8
Avg EPS beat(12)-4.65%
EPS beat(16)11
Avg EPS beat(16)-3.59%
Revenue beat(2)0
Avg Revenue beat(2)-2.03%
Min Revenue beat(2)-3.78%
Max Revenue beat(2)-0.28%
Revenue beat(4)1
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-3.78%
Max Revenue beat(4)1.48%
Revenue beat(8)4
Avg Revenue beat(8)0.61%
Revenue beat(12)5
Avg Revenue beat(12)0.43%
Revenue beat(16)8
Avg Revenue beat(16)0.59%
PT rev (1m)1.22%
PT rev (3m)1.22%
EPS NQ rev (1m)117.14%
EPS NQ rev (3m)117.14%
EPS NY rev (1m)4.34%
EPS NY rev (3m)1.73%
Revenue NQ rev (1m)1.32%
Revenue NQ rev (3m)1.32%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 166.86
P/S 3.57
P/FCF N/A
P/OCF N/A
P/B 150.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)0.08
Fwd EY0.6%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS3.92
BVpS0.09
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.15%
ROE -941.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.94%
FCFM N/A
ROA(3y)-30.87%
ROA(5y)-41.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5YN/A
F-Score5
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 20.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.09%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 2.23
Altman-Z -0.1
F-Score5
WACC10.25%
ROIC/WACCN/A
Cap/Depr(3y)42.66%
Cap/Depr(5y)56.66%
Cap/Sales(3y)1.25%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y55.54%
EPS Next 2Y46.12%
EPS Next 3Y49.27%
EPS Next 5Y45.98%
Revenue 1Y (TTM)34.42%
Revenue growth 3Y52.93%
Revenue growth 5YN/A
Sales Q2Q%22.12%
Revenue Next Year32.14%
Revenue Next 2Y32.03%
Revenue Next 3Y32.11%
Revenue Next 5Y28.76%
EBIT growth 1Y28.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.23%
EBIT Next 3Y63.18%
EBIT Next 5Y63.78%
FCF growth 1Y70.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.18%
OCF growth 3YN/A
OCF growth 5YN/A